

PCT  
JC07 Rec'd PCT/PTO 15 MAR 2002


Patent Docket P2534-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 03 2002

TECH CENTER 1600/2900

In re Application of  Audrey D. Goddard et al.  Serial No.: 09/869,566  Filed: June 29, 2001  For: II-1 RELATED POLYPEPTIDES	Group Art Unit: Not yet assigned  Examiner: Not yet assigned  <b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, PO Box 2327, Arlington, VA 22202 on  March 12, 2002  Emily Dutra
--	--

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in 37 CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

**A copy of the items on PTO-1449 is supplied herewith.**

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-())" (nucleotide) and "BLAST Results B-1 - B-())" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.


In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

By:



Craig G. Svoboda

Reg. No. 39,044

Telephone No. (650) 225-1489

Date: March 11<sup>th</sup>, 2002



09157

PATENT TRADEMARK OFFICE

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P2534-3

Serial No.

09/869,599

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Goddard et al.

Filing Date

29 Jun 2001

Group

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	1	855,404	29.07.98	EP				
	2	WO 95/10298	20.04.95	PCT				
	3	WO 99/06426 ✓	11.02.99	PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	4	Altschul et al., "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs." <u>Nucleic Acids Research</u> . 25(17):3389-3402 (1997)
	5	Bazan et al., "A Newly Defined Interleukin-1?" <u>Nature</u> . 379:591 (Feb 15, 1996)
	6	Dinareello et al., "Overview of Interleukin-18: More Than an Interferon-γ Inducing Factor." <u>J. Leukocyte Biol.</u> 63:658-664 (Jun 1998)
	7	Dinareello, C.A., "Biologic Basis for Interleukin-1 in Disease." <u>Blood</u> . 87(6):2095-2147 (Mar 15, 1996)
	8	Eisenberg et al., "Interleukin-1 Receptor Antagonist is a Member of the Interleukin-1 Gene Family: Evolution of a Cytokine Control Mechanism." <u>Proc. Natl. Acad. Sci. (USA)</u> 88:5232-5236 (Jun 1991)
	9	Eisenberg et al., "Primary Structure and Functional Expression From Complementary DNA of a Human Interleukin-1 Receptor Antagonist." <u>Nature</u> . 343:341-346 (Jan 1990)
	10	Haskill et al., "cDNA Cloning of an Intracellular Form of the Human Interleukin 1 Receptor Antagonist Associated With Epithelium." <u>Proc. Natl. Acad. Sci. (USA)</u> 88:3681-3685 (May 1991)
	11	Matsushime et al., "Cloning and Expression of Murine Interleukin-1 Receptor Antagonist in Macrophages Stimulated by Colony-Stimulating Factor 1." <u>Blood</u> . 78(3):616-623 (Aug 1991)
	12	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL." <u>Science</u> . 276:111-113 (Apr 4, 1997)
	13	Shuck et al., "Cloning, Heterologous Expression and Characterization of Murine Interleukin-1 Receptor Antagonist Protein." <u>European Journal of Immunology</u> 21:2775-2780 (1991)
	14	Zahedi et al., "Mouse IL-1 Receptor Antagonist Protein: Molecular Characterization, Gene Mapping, and Expression of mRNA in Vitro and in Vivo." <u>J. Immunol.</u> 146(12):4228-4233 (Jun 1991)
	15	Zahedi et al., "The Mouse Interleukin 1 Receptor Antagonist Protein: Gene Structure and Regulation In Vitro." <u>Cytokine</u> . 6(1):1-9 (Jan 1994)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.